


Electronic Supplementary Material (ESI) for Food & Function. This journal is © The Royal Society of Chemistry 2020




**Fig. S1** Linear correlation between target compound content and in vitro mammalian  $\alpha$ -glucosidase inhibition achieved at 160 µg mL<sup>-1</sup> by (a) ten xanthone-enriched fractions (XEFs) and (b) ten benzophenone-enriched fractions (BEFs) of *Cyclopia genistoides*, tested in triplicate (n = 30 for XEFs and BEFs).




**Fig. S2** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 1: acarbose (Aca) with benzophenone-enriched fraction (BEF<sub>0</sub>) (generated by CompuSyn Version 1.0).




**Fig. S3** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 2: acarbose (Aca) with xanthone-enriched fraction (XEF<sub>0</sub>) (generated by CompuSyn Version 1.0).




**Fig. S4** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 3: acarbose (Aca) with mangiferin (MGF) (generated by CompuSyn Version 1.0).




**Fig. S5** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 4: acarbose (Aca) with isomangiferin (IMGF) (generated by CompuSyn Version 1.0).




**Fig. S6** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 5: acarbose (Aca) with 3- $\beta$ -D-glucopyranosyliriflophenone (I3G) (generated by CompuSyn Version 1.0).




**Fig. S7** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 6: acarbose (Aca) with 3- $\beta$ -D-glucopyranosyl-4-O- $\beta$ -D-glucopyranosyliriflophenone (IDG) (generated by CompuSyn Version 1.0).




**Fig. S8** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 7: benzophenone-enriched fraction (BEF<sub>0</sub>) with xanthone-enriched fraction (XEF<sub>0</sub>) (generated by CompuSyn Version 1.0).




**Fig. S9** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a$  = 0.25, 0.50 and 0.75 for combination 8: mangiferin (MGF) with isomangiferin (IMGF) (generated by CompuSyn Version 1.0).




**Fig. S10** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 9: mangiferin (MGF) with 3- $\beta$ -D-glucopyranosyliriflophenone (I3G) (generated by CompuSyn Version 1.0).




**Fig. S11** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 10: isomangiferin (IMGF) with 3- $\beta$ -D-glucopyranosyliriflophenone (I3G) (generated by CompuSyn Version 1.0).



**Fig. S12** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 11: 3- $\beta$ -D-glucopyranosyl-4-O- $\beta$ -D-glucopyranosyliriflophenone (IDG) with 3- $\beta$ -D-glucopyranosyliriflophenone (I3G) (generated by CompuSyn Version 1.0).



**Fig. S13** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 12: 3- $\beta$ -D-glucopyranosyl-4-O- $\beta$ -D-glucopyranosyliriflophenone (IDG) with mangiferin (MGF) (generated by CompuSyn Version 1.0).



**Fig. S14** (a) Effect level ( $F_a$ ) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at  $F_a = 0.25$ , 0.50 and 0.75 for combination 13: 3- $\beta$ -D-glucopyranosyl-4-O- $\beta$ -D-glucopyranosyliriflophenone (IDG) with isomangiferin (IMGF) (generated by CompuSyn Version 1.0).